Cluster Headaches are an uncommon, severe form of primary neurovascular headaches. It is the most painful form of headaches, with the pain occurring on one side of the head and behind or above the eye or at the temple, most commonly. 

Cluster Headache patients have typical trigeminal-autonomic symptoms, such as ptosis, sweating, and miosis. In addition to trigeminal-autonomic symptoms, a large proportion of patients with Cluster Headaches have migraine-like features such as photophobia or osmophobia; thus, many patients are not correctly diagnosed and are misdiagnosed with a migraine disorder instead.

According to DelveInsight’s analysts, the total prevalent Cluster Headache population in the 7MM countries was estimated to be 877,859 cases in 2020. A higher percentage of the male population is affected by Cluster Headache as compared to the female population. 

 

DelveInsight’s “Cluster Headache Market“ report provides a thorough comprehension of the Cluster Headache, historical and forecasted epidemiology, and the Cluster Headache market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Cluster Headache market report also proffers an analysis of the current Cluster Headache treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

 

For further information on Market Impact by Therapies, visit: Global Cluster Headache Drug Treatment Market

 

Some of the key takeaways of the Cluster Headache Market Research Report 

• Many patients are undertreated, and in some cases, not treated. Cluster Headache patients are more likely to use prescription and nonprescription pain medications, including opiates.
• Verapamil is the first choice drug in the preventive treatment of Cluster Headache. Some of the most promising drugs include Triptans, Analgesics, Verapamil, Emgality, among others. 
• The major key players include Lundbeck Seattle BioPharmaceutical, Winston Laboratories, Zosano Pharma, Eli Lilly and Company, and others that hold the potential to create a significant drag in the Cluster Headache market.
• The Cluster Headache market is expected to gain traction, attributed to increased prevalence and the expected launch of novel therapies, such as Eptinezumab, Civamide, Zolmitriptan, and others during the forecast period (2018–2030). The Cluster Headache market has a promising outlook with the launch of drugs such as Emgility in 2020, and with emerging drugs such as Eptinezumab and Civamide which are expected to enter the United States market by 2024 and 2025 respectively. 

 

The Cluster Headache Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Cluster Headache Prevalence
• Cluster Headache Diagnosed Cases 
• Type-specific Cases of Cluster Headache
• Gender-specific Cases of Cluster Headache
• Age-specific Cases of Cluster Headache 

 

Get a sample copy of this report: Cluster Headache Market Landscape

 

Cluster Headache Emerging Therapies Along with Key Players

• VYEPTI (Eptinezumab): Lundbeck Seattle BioPharmaceutical
• Civamide (Zucapsaicin): Winston Laboratories
• Zolmitriptan transdermal (C213): Zosano Pharma 

And several others.

To conclude, Cluster Headache Market Growth will upsurge due to the launch of emerging therapies that are better in efficacy and/or with a more favorable safety profile, the development of a genetic approach, and a large cohort of patients. Since the entire landscape was till recently was devoid of any effective pharmaceutical treatment option, any significant development in this direction is expected to create a tectonic impact on the existing market scenario nevertheless, clinical trials challenges, economic burden, and lack of doctor’s knowledge regarding the disease will hinder Cluster Headache Market.

 

Scope of the Cluster Headache Market Insight Report 

• Geography Covered: 7MM – The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 10-year forecasted analysis (2019-2032).
• Cluster Headache Markets Segmentation: By Geographies and By Cluster Headache Therapies (Historical and Forecasted, Current and Upcoming) 
• Dominant Market Companies investigating its candidates for Cluster Headache: Lundbeck Seattle BioPharmaceutical, Winston Laboratories, and Zosano Pharma, Eli Lilly and Company, and several others.
• Analysis: Comparative and conjoint analysis of emerging therapies. 
• Case Studies
• KOL’s Views
• Analyst’s View

 

 

Table of Contents 

1	Cluster Headache Key Insights
2	Cluster Headache Report Introduction
3	Cluster Headache Market Overview at a Glance
4	Executive Summary of Cluster Headache
5	Cluster Headache Disease Background and Overview
6	Cluster Headache Epidemiology and Patient Population
7	7MM Total Diagnosed Cluster Headache Prevalent Population
7.1	The United States
7.2	EU5 Countries
7.2.1	Germany
7.2.2	France
7.2.3	Italy
7.2.4	Spain
7.2.5	The United Kingdom
7.3	Japan
8	Cluster Headache Case Reports
9	Cluster Headache Marketed Products
9.1	EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company
10	Cluster Headache Emerging Drugs
10.1	VYEPTI (Eptinezumab): Lundbeck Seattle BioPharmaceutical
10.2	Civamide (Zucapsaicin): Winston Laboratories
11	Other Cluster Headache Drugs under Development
11.1	Zolmitriptan transdermal (C213): Zosano Pharma
12	7MM Cluster Headache Market Analysis
12.1	The United States Cluster Headache Market Size
12.2	EU-5 Cluster Headache Market Size
12.2.1	Germany Market Size
12.2.2	France Market Size
12.2.3	Italy Market Size
12.2.4	Spain Market Size
12.2.5	The United Kingdom Market Size
12.3	Japan Cluster Headache Market Size
13	KOL Views
14	Cluster Headache Market Drivers
15	Cluster Headache Market Barriers
16	SWOT Analysis of Cluster Headache
17	Cluster Headache Unmet Needs
18	Cluster Headache Market Access
19	Appendix
20	DelveInsight Capabilities
21	Disclaimer
22	About DelveInsight

 

Other Reports:

Partial Seizure Market

DelveInsight’s “Partial Seizure Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Partial Seizure, historical and forecasted epidemiology as well as the Partial Seizure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/cluster-headache-market